Can Apple's new ResearchKit really transform drug R&D?

Amid all the pomp, circumstance and sans serif fonts in Apple's ($APPL) latest product launch, the company took a break from pumping expensive new gadgetry to unveil a piece of software with the potential to change the medical research landscape. Dubbed ResearchKit, Apple's new platform promises to transform the world's hundreds of millions of iPhones into handheld gatherers of clinical data, which some say will usher in a new era of biomedical science but could well amount to more questions than answers. Report

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.